Dianthus Therapeutics DNTH
NASDAQ DNTH
$89.30 +0.49 (+0.55%)
At close: Nov 11, 2026 · 4:00 PM EST

Dianthus Therapeutics (DNTH) Net Income Attributable to Noncontrolling Interests (2019 - 2025)

Updated

Analysis

Dianthus Therapeutics (DNTH) Net Income Attributable to Noncontrolling Interests (2019 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -1.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 10.00 Mn
10 Dianthus Therapeutics 5.00 Bn 4.95 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 326,000.00
Sep 30, 2025 65,000.00
Dec 31, 2024 -575,000.00
Sep 30, 2024 718,000.00
Dec 31, 2023 51,000.00
Sep 30, 2023 15,000.00
Mar 31, 2021 32,000.00
Mar 31, 2020 355,000.00
Jun 30, 2019 98,000.00
Mar 31, 2019 49,000.00
API Access

Dianthus Therapeutics Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=DNTH&period=max&api_key=YOUR_API_KEY